The Anemia in Chronic Kidney Disease (Renal Anemia) drugs in development market research report provides comprehensive information on the therapeutics under development for Anemia in Chronic Kidney Disease (Renal Anemia), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Anemia in Chronic Kidney Disease (Renal Anemia). Buy the report here.
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Anemia in Chronic Kidney Disease (Renal Anemia) and features dormant and discontinued products.
GlobalData tracks 42 drugs in development for Anemia in Chronic Kidney Disease (Renal Anemia) by 42 companies/universities/institutes. The top development phase for Anemia in Chronic Kidney Disease (Renal Anemia) is preclinical with 11 drugs in that stage. The Anemia in Chronic Kidney Disease (Renal Anemia) pipeline has 41 drugs in development by companies and one by universities/ institutes. Some of the companies in the Anemia in Chronic Kidney Disease (Renal Anemia) pipeline products market are: 3SBio, UBI Pharma and Disc Medicine.
The key targets in the Anemia in Chronic Kidney Disease (Renal Anemia) pipeline products market include Erythropoietin Receptor (EPOR), Egl Nine Homolog 1 (Hypoxia Inducible Factor Prolyl Hydroxylase 2 or Prolyl Hydroxylase Domain Containing Protein 2 or SM 20 or EGLN1 or EC 1.14.11.29), and Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.).
The key mechanisms of action in the Anemia in Chronic Kidney Disease (Renal Anemia) pipeline product include Erythropoietin Receptor (EPOR) Agonist with 22 drugs in Pre-Registration. The Anemia in Chronic Kidney Disease (Renal Anemia) pipeline products include six routes of administration with the top ROA being Intravenous and eight key molecule types in the Anemia in Chronic Kidney Disease (Renal Anemia) pipeline products market including Recombinant Protein, and Small Molecule.
Anemia in Chronic Kidney Disease (Renal Anemia) overview
Renal anemia is a disease in which the patient has an unusually low count of red blood cells associated with kidney disease. This type of anemia is caused by a lack of erythropoietin, a protein produced in the kidneys that helps to create red blood cells. Symptoms caused by renal anemia include pale skin and gums, shortness of breath, dizziness, and inability to think clearly.
For a complete picture of Anemia in Chronic Kidney Disease (Renal Anemia)’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
